Cargando…

Targeting the Pim kinases in multiple myeloma

Multiple myeloma (MM) is a plasma cell malignancy that remains incurable. Novel treatment strategies to improve survival are urgently required. The Pims are a small family of serine/threonine kinases with increased expression across the hematological malignancies. Pim-2 shows highest expression in M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keane, N A, Reidy, M, Natoni, A, Raab, M S, O'Dwyer, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526774/ https://www.ncbi.nlm.nih.gov/pubmed/26186558 http://dx.doi.org/10.1038/bcj.2015.46

Ejemplares similares

PIM Kinases in Multiple Myeloma
por: Wu, Jian, et al.
Publicado: (2021)

Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment
por: Natoni, Alessandro, et al.
Publicado: (2019)

An overview of pim kinase as a target in multiple myeloma
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
por: Daly, John, et al.
Publicado: (2022)

Pim-2 Kinase Regulates Energy Metabolism in Multiple Myeloma
por: Liu, Zhaoyun, et al.
Publicado: (2022)

Targeting PIM Kinases to Improve the Efficacy of Immunotherapy
por: Clements, Amber N., et al.
Publicado: (2022)

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
por: Paíno, Teresa, et al.
Publicado: (2020)

Targeting Selectins and Their Ligands in Cancer
por: Natoni, Alessandro, et al.
Publicado: (2016)

PIM Kinase as an Executional Target in Cancer
por: Zhang, Xinning, et al.
Publicado: (2018)

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
por: Swan, Dawn, et al.
Publicado: (2019)

New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim, Cian, et al.
Publicado: (2017)

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models
por: Natoni, Alessandro, et al.
Publicado: (2013)

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271
por: Natoni, A, et al.
Publicado: (2017)

Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma
por: Nair, Jayakumar R., et al.
Publicado: (2016)

Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model
por: Natoni, Alessandro, et al.
Publicado: (2020)

Targeting Pim kinases in hematological cancers: molecular and clinical review
por: Bellon, Marcia, et al.
Publicado: (2023)

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
por: Swan, Dawn, et al.
Publicado: (2020)

Adoptive Immunotherapy and High-Risk Myeloma
por: Duane, Catherine, et al.
Publicado: (2023)

Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics
por: Wang, Yixin, et al.
Publicado: (2021)

PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020)

Pim2 is important for regulating DNA damage response in multiple myeloma cells
por: Ramachandran, J, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma
por: Stafman, Laura L., et al.
Publicado: (2018)

PIM kinases as therapeutic targets against advanced melanoma
por: Shannan, Batool, et al.
Publicado: (2016)

The Role of PIM Kinases in Pediatric Solid Tumors
por: Julson, Janet Rae, et al.
Publicado: (2022)

Pim Kinases: Important Regulators of Cardiovascular Disease
por: Nock, Sophie, et al.
Publicado: (2023)

P811: PIM2 KINASE REGULATES TIGIT EXPRESSION AND ENERGY METABOLISM IN NK CELLS OF PATIENTS WITH MULTIPLE MYELOMA
por: Liu, Zhaoyun, et al.
Publicado: (2023)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Targeting PIM kinases to oppose hypoxia-mediated therapeutic resistance
por: Chauhan, Shailender S., et al.
Publicado: (2018)

P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY
por: Natoni, A., et al.
Publicado: (2022)

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
por: Mahalingam, D, et al.
Publicado: (2011)

The role of PIM1/PIM2 kinases in tumors of the male reproductive system
por: Jiménez-García, Manuel Pedro, et al.
Publicado: (2016)

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
por: Moore, Gillian, et al.
Publicado: (2021)

A review on PIM kinases in tumors
por: Arrouchi, Housna, et al.
Publicado: (2019)

Dysphonia and dysphagia consequences of paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS)
por: Halfpenny, Rhiannon, et al.
Publicado: (2021)

Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion
por: Santio, Niina M, et al.
Publicado: (2010)

Targeting Host PIM Protein Kinases Reduces Mayaro Virus Replication
por: Sugasti-Salazar, Madelaine, et al.
Publicado: (2022)

Targeting Echinococcus multilocularis PIM kinase for improving anti-parasitic chemotherapy
por: Koike, Akito, et al.
Publicado: (2022)

The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas
por: Forshell, Linus Plym, et al.
Publicado: (2011)

Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma()()
por: Stafman, Laura L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j3vvn040e80mmhmcml51tdf8ng